2013 American Transplant Congress
Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Two Years Result of a Japanese Multicenter Study
(Aims) Mizoribine (MZR) has been developed as an immunosuppressive agent, but has a less potent immunosuppressive effect up to 3 mg/kg/day. The widespread use of…2013 American Transplant Congress
Behavior of ADAMTS13 and Von Willebrand Factor Levels in Patients after Living Donor Liver Transplantation
Introduction : Thrombotic microangiopathy (TMA) is one of the important complications occurring after liver transplantation (LT), and it is suggested that a Von Willebrand factor…2013 American Transplant Congress
Combination of Anti-BTLA Antibody (6B2) and Anti-PD-1 Antibody (PIM-2) Induced Indefinite Survival of Fully MHC-Mismatched Murine Cardiac Allograft
Background: Programmed death (PD)-1 has been implicated in peripheral tolerance, and the coinhibitory receptor B and T lymphocyte attenuator (BTLA) has been implicated in the…2013 American Transplant Congress
Agonistic Anti-BTLA mAb (3C10) Induced Prolongation of Murine Cardiac Allograft and Generation of IL-10 Dependent Regulatory CD4+ T Cells, An
Background: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA) has been implicated in the regulation of autoimmunity and may potentially play an important role…2013 American Transplant Congress
Effect of Donor Right Hepatectomy on Regeneration of the Liver and the Spleen
Surgery, Seoul St Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea
Purpose: Donor hepatectomy for living donor liver transplantation accompanies physiomorphological changes of the liver and the spleen. Therefore, the long-term consequences of these organs should…2013 American Transplant Congress
Effect of Sirtuin 1 Gene Expression on Mouse Islet Graft Survival, The
Purpose: Islet transplantation is a promising therapy for Type 1 diabetes, however clinical application has not been as successful as organ transplantation due to early…2013 American Transplant Congress
Efficacy and Safety of 3 vs. 6 Months of Low-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Moderate-Risk (D+/R+) Renal Transplant Recipients Receiving Antilymphocyte Antibody Induction Therapy
Multicenter CMV Pharmacists Collaborative Study Group, Boston
The cytomegalovirus (CMV) donor-positive/recipient-positive (D+/R+) population represents the largest group of at-risk renal transplant recipients (RTR). Practice guidelines on the prevention of CMV recommend prophylaxis…2013 American Transplant Congress
Distinct Roles of CD137 and CD137L Bidirectional Signals in Candida albicans Infection
Invasive fungal infections by Candida albicans frequently cause mortality in immunocompromised patients, yet the cellular processes leading to this mortality remain ill-defined. Here, using genetic…2013 American Transplant Congress
Effect of Plasmapheresis on Angiotensin II Type I Receptor Antibody
The presence of angiotensin II type I receptor (AT1R) antibody has been associated with renal allograft rejection. We determined the presence of AT1R antibody in…2013 American Transplant Congress
Low-Dose Cyclosporine (CsA) Plus Mycophenolate Mofetil (MMF) and Prednisolone (Pred) Triple Immunosuppressive Protocol in Renal Transplantation
BACKGROUND: In order to decrease the rate of adverse effects of cyclosporin, a low-dose CsA plus MMF and Pred triple immunosuppressive protocol was started from…
American Transplant Congress abstracts